Management of Acute Deep Vein Thrombosis in Patients on Prophylactic Apixaban

Assessment and Treatment Initiation

The American College of Chest Physicians recommends extended anticoagulation for patients with recurrent unprovoked VTE, and breakthrough thrombosis on inadequate anticoagulation functionally represents recurrent disease 1, 2
Medication adherence, drug interactions, underlying hypercoagulable conditions, and anatomical factors should be verified before proceeding with treatment 1
Extended anticoagulation (indefinite duration) is recommended for patients who develop breakthrough DVT despite being on anticoagulation 1, 2

If active malignancy is present, consider switching to low-molecular-weight heparin (LMWH) as first-line therapy, as LMWH is preferred over DOACs in cancer-associated thrombosis 2, 3
If no cancer but high bleeding risk, consider dose reduction to apixaban 2.5mg BID for extended therapy after completing 6 months of therapeutic anticoagulation 3, 4

Outpatient management is appropriate if the patient is hemodynamically stable, has adequate home support, phone access, and ability to return if deterioration occurs, and no contraindications to anticoagulation 1, 5
Early ambulation is recommended over bed rest 1

Reassess at 3 months to confirm therapeutic response and tolerance 2
After 6 months of therapeutic dosing, consider transition to reduced-dose apixaban 2.5mg BID if bleeding risk is acceptable 3, 4
Annual reassessment of bleeding risk, renal function, and indication for continued anticoagulation is mandatory 1, 3